Atria Investments Inc Makes New Investment in Masimo Co. (NASDAQ:MASI)

Atria Investments Inc acquired a new stake in Masimo Co. (NASDAQ:MASI - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 2,026 shares of the medical equipment provider's stock, valued at approximately $335,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC raised its stake in shares of Masimo by 31.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 250 shares of the medical equipment provider's stock valued at $42,000 after purchasing an additional 60 shares in the last quarter. Blue Trust Inc. raised its stake in shares of Masimo by 56.3% in the 4th quarter. Blue Trust Inc. now owns 197 shares of the medical equipment provider's stock valued at $33,000 after purchasing an additional 71 shares in the last quarter. CIBC Asset Management Inc raised its stake in shares of Masimo by 5.6% in the 4th quarter. CIBC Asset Management Inc now owns 1,631 shares of the medical equipment provider's stock valued at $270,000 after purchasing an additional 87 shares in the last quarter. MML Investors Services LLC raised its stake in shares of Masimo by 4.9% in the 3rd quarter. MML Investors Services LLC now owns 2,056 shares of the medical equipment provider's stock valued at $274,000 after purchasing an additional 96 shares in the last quarter. Finally, Louisiana State Employees Retirement System raised its stake in shares of Masimo by 0.8% in the 4th quarter. Louisiana State Employees Retirement System now owns 12,300 shares of the medical equipment provider's stock valued at $2,033,000 after purchasing an additional 100 shares in the last quarter. 85.96% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Insider Activity at Masimo

In related news, Director Craig B. Reynolds sold 2,053 shares of the company's stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares in the company, valued at approximately $2,754,601.53. This represents a 11.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Bilal Muhsin sold 30,000 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $167.49, for a total transaction of $5,024,700.00. Following the completion of the sale, the chief operating officer now owns 24,172 shares of the company's stock, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The disclosure for this sale can be found here. 9.70% of the stock is owned by insiders.

Masimo Price Performance

Shares of Masimo stock traded down $3.68 on Friday, hitting $165.82. The company had a trading volume of 695,723 shares, compared to its average volume of 623,638. The business has a 50-day simple moving average of $175.00 and a 200-day simple moving average of $158.86. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The company has a market cap of $8.95 billion, a PE ratio of 114.36 and a beta of 1.04. Masimo Co. has a 52 week low of $101.61 and a 52 week high of $194.88.

Masimo (NASDAQ:MASI - Get Free Report) last posted its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.42 by $0.38. The business had revenue of $600.70 million during the quarter, compared to analysts' expectations of $593.35 million. Masimo had a net margin of 3.85% and a return on equity of 14.98%. Research analysts expect that Masimo Co. will post 4.1 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on MASI. Piper Sandler upped their target price on shares of Masimo from $210.00 to $215.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Stifel Nicolaus reiterated a "buy" rating and set a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Wednesday, February 26th. Raymond James increased their price objective on shares of Masimo from $170.00 to $194.00 and gave the stock an "outperform" rating in a research note on Friday, December 27th. Finally, Wells Fargo & Company increased their price objective on shares of Masimo from $193.00 to $205.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $194.80.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.